about
Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort.Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort.Cognitive dysfunction and functional magnetic resonance imaging in systemic lupus erythematosus.Microparticle subpopulations are potential markers of disease progression and vascular dysfunction across a spectrum of connective tissue disease.SLE and metabolic syndrome.Endothelial microparticles: Pathogenic or passive players in endothelial dysfunction in autoimmune rheumatic diseases?Can we identify who gets benefit or harm from mycophenolate mofetil in systemic lupus erythematosus? A systematic review.Predictive and prognostic factors influencing outcomes of rituximab therapy in systemic lupus erythematosus (SLE): A systematic review.The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales.The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales.Clinicians approaches to management of background treatment in patients with SLE in clinical remission: results of an international observational survey.Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register.The Association of Baseline and Longitudinal Change in Endothelial Microparticle Count with Mortality in Chronic Kidney Disease.Certolizumab pegol attenuates the pro-inflammatory state in endothelial cells in a manner that is atheroprotective.The metabolic syndrome in systemic lupus erythematosusAn analysis of the metabolic syndrome phenotype in systemic lupus erythematosus
P50
Q30560952-8F431E4F-D02C-40E3-B886-9B034BAAD5FCQ30791606-1F70AD93-413F-402D-A6A7-3E015C86020CQ30977603-65597AF8-F1A4-4DAC-A61A-CD7D285F6ED5Q37544731-94216954-5803-4B50-9FE8-5324EA2A0C02Q38149853-4F0E6729-91BF-4292-9940-41F4E146B812Q38854487-4F5C91ED-558B-4A92-9A5A-F2C6073B58AEQ39191455-41C6FAAB-BDD2-4478-9D10-786A7F5DD241Q39364970-127A0E0A-B199-46F4-8202-BFE6C5CC1FC1Q40183925-2031F535-F488-49F2-B073-44E7E2F98F8BQ40232762-4FBF6CE2-2866-4E81-BDEE-1EE93FA2846AQ47133837-0D910583-CB28-4B6D-A794-A99F6FA60204Q47687376-B504A293-25FB-410C-9E16-2C7BF0624ADBQ52921049-2216AF5D-29FC-4CCE-BB97-5805A4508146Q54276887-5704AAF1-0873-4E59-9D97-75664D60C8D0Q83129571-C5DEED34-5297-4325-AE81-ACB8CCBAC7E3Q84892878-21C1131F-F466-4D34-B00A-D50A27D219F6
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Ben Parker
@ast
Ben Parker
@en
Ben Parker
@es
Ben Parker
@nl
type
label
Ben Parker
@ast
Ben Parker
@en
Ben Parker
@es
Ben Parker
@nl
prefLabel
Ben Parker
@ast
Ben Parker
@en
Ben Parker
@es
Ben Parker
@nl
P106
P31
P496
0000-0001-7959-6529